Development of Cystic Fibrosis Treatment Nets $8.9M for Antabio

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, a public-private partnership devoted to antibacterial R&D. Antabio was selected by CAR...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical Processing
Main Author SAS, Antabio
Format Trade Publication Article
LanguageEnglish
Published Rockaway Advantage Business Media 26.07.2017
Subjects
Antibiotics
Awards & honors
Cystic fibrosis
Disease
Drug resistance
Funding
Immune system
Infections
Infectious diseases
Pharmaceutical industry
R&D
Research & development
Virulence
Europe
Online AccessGet full text

Cover

More Information
Summary:Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, a public-private partnership devoted to antibacterial R&D. Antabio was selected by CARB-X from a group of 368 applicants worldwide and is part of the first cohort that includes companies from continental Europe. The funding will be used to accelerate the development, up to completion of...
ISSN:1049-9156